BCL2L1 and central nervous system cancer: Vandetanib inhibits signaling pathways activated by EGFRvIII, such as STAT3, AKT, and Bcl-xL, thus reducing cell growth and angiogenesis in glioma cell lines that express EGFRvIII [250].